Compare CRGO & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRGO | ACET |
|---|---|---|
| Founded | 2012 | 1947 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.7M | 79.9M |
| IPO Year | 2022 | 2017 |
| Metric | CRGO | ACET |
|---|---|---|
| Price | $1.34 | $8.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.40 | ★ $48.33 |
| AVG Volume (30 Days) | 37.9K | ★ 83.8K |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.61 | N/A |
| Revenue Next Year | $16.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.14 | $0.46 |
| 52 Week High | $4.24 | $9.84 |
| Indicator | CRGO | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 46.13 |
| Support Level | $1.17 | $7.45 |
| Resistance Level | $1.43 | $8.68 |
| Average True Range (ATR) | 0.06 | 0.52 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 78.85 | 31.47 |
Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters, thousands of forwarders, and dozens of airlines and ocean carriers. The company operates in two segments: the Platform segment and the Solutions segment. The majority of the revenue is derived from the Solutions segment, which provides software tools and data to help industry participants automate their pricing, sales, and procurement processes. Geographically, it generates the maximum revenue from Europe, and the rest from the United States, Hong Kong and Others.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).